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and Fluoroscopic Guidance
Feasibility and 30-Day Outcomes
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Christophe Tron, MD,* Pierre-Yves Litzler, MD, PHD,† Jean-Paul Bessou, MD,†
Karim Bejar, MD,* Chiara Fraccaro, MD,* Carlos Sanchez-Giron, MD,*
Jean-Nicolas Dacher, MD, PHD,‡ Fabrice Bauer, MD, PHD,* Alain Cribier, MD,*
Hélène Eltchaninoff, MD*
Rouen, France
Objectives The authors report the feasibility and 30-day outcomes of transfemoral aortic valve replacement
(TAVR), using the Edwards SAPIEN (Edwards Lifesciences, Irvine, California) and Edwards SAPIEN XT (Edwards
Lifesciences) prosthesis, implanted using exclusively local anesthesia and ﬂuoroscopic guidance.
Background Transfemoral TAVR is often managed with general anesthesia. However, a simpliﬁed
percutaneous approach using local anesthesia has become more popular because it offers multiple
advantages in an elderly and fragile population.
Methods Between May 2006 and January 2011, the authors prospectively evaluated 151 consecu-
tive patients (logistic EuroSCORE: 22.8  11.8%) who underwent TAVR (SAPIEN: n  78, SAPIEN XT:
n  73) using only local anesthesia and ﬂuoroscopic guidance. The primary endpoint was a combi-
nation of all-cause mortality, major stroke, life-threatening bleeding, stage 3 acute kidney injury
(AKI), periprocedural myocardial infarction (MI), major vascular complication, and repeat procedure
for valve-related dysfunction at 30 days.
Results Transarterial femoral approach was surgical in all SAPIEN procedures and percutaneous in
97.3% of SAPIEN XT, using the ProStar vascular closure device, and was well tolerated in all cases. Con-
version to general anesthesia was required in 3.3% (SAPIEN cases) and was related to complications. Va-
sopressors were required in 5.5%. Procedural success was 95.4%. The combined-safety endpoint was
reached in 15.9%, including overall mortality (6.6%), major stroke (2.0%), life-threatening bleeding (7.9%),
stage 3 AKI (0.7%), periprocedural MI (1.3%), major vascular complication (7.9%), and repeat procedure
for valve-related dysfunction (2.0%) at 30 days. A permanent pacemaker was required in 5.3%.
Conclusions This single-center, prospective registry demonstrated the feasibility and safety of a simpli-
ﬁed transfemoral TAVR performed using only local anesthesia and ﬂuoroscopic guidance in high surgical
risk patients with severe aortic stenosis. (J Am Coll Cardiol Intv 2012;5:461–7) © 2012 by the American
College of Cardiology Foundation
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462Since the first-in-man transfemoral aortic valve replacement
(TAVR) in 2002, many registries have shown that TAVR
can be accomplished in high-risk patients with outcomes
that compare favorably with surgical aortic valve replace-
ment (1–8). This has been observed with the 2 devices
currently used, the balloon-expandable Edwards SAPIEN
(Edwards Lifesciences, Irvine, California) and the self-
expandable Medtronic CoreValve (Medtronic CV, Irvine,
California) prosthesis. Recently, using the Edwards SA-
PIEN device, the pivotal randomized PARTNER-US
(Placement of Aortic Transcatheter Valve) trial demon-
strated the superiority of TAVR over standard care with
See page 468
reduction of death at 1 year in nonsurgical candidates and a
similar rate of survival at 1 year with TAVR and surgical
aortic valve replacement in high surgical risk patients (9,10).
As a consequence, the number
of TAVR and the number of
centers are dramatically increas-
ing worldwide.
Among the current approaches
used for TAVR, transfemoral ac-
cess is generally the first choice for
the majority of investigators. The
CoreValve is delivered through an
18-F sheath whereas the 23- and
26-mm Edwards SAPIEN valves
require a 22- and 24-F sheath,
respectively. Since October 2009,
the new generation of Edwards
valves, the SAPIEN XT valve, has
decreased the required sheath size
to 18- and 19-F, respectively.
Initially, because of the large
caliber of the Edwards sheath, the femoral artery was generally
accessed surgically, and the procedure was performed under
general anesthesia. With the decrease in sheath sizes, an
increasing number of operators have switched to a percutane-
ous approach performed using local anesthesia. However, with
this simplified technique, intraprocedural transesophageal
echocardiography (TEE), which has been advised as a helpful
adjunct for valve positioning, assessment of the results, and
detection of complications, is not used.
Interestingly, since the first-in-man implantation in
2002, our group has performed transfemoral cases using
exclusively local anesthesia and fluoroscopic guidance for
valve implantation without intraprocedural TEE (1,2).
Thus, we sought to report the feasibility and safety of this
received lecture fees from Edwards Lifesciences. All other authors have reported that
Abbreviations
and Acronyms
BAV  balloon aortic
valvuloplasty
CT  computed tomography
MI  myocardial infarction
RVP  rapid ventricular
pacing
TAVR  transfemoral aortic
valve replacement
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiography
VARC  Valve Academic
Research Consortiumthey have no relationships relevant to the contents of this paper to disclose.
M
2strategy in our series of patients entered in a prospective
registry using Edwards SAPIEN and SAPIEN XT valves.
Methods
Patient selection. Between May 2006 and May 2011, 151
consecutive patients (mean age: 83.3 years, 58.9% female) in
whom transfemoral TAVR was performed were included in
a prospective, single-center registry. All patients selected by
our multidisciplinary team had severe, degenerative aortic
stenosis and were included with respect to the inclusion
criteria of successive European trials and registries (3,5,6).
All patients gave written informed consent.
In our group, the screening process included transthoracic
echocardiography (TTE), selective coronary angiography,
aortography, and iliofemoral angiography. TEE was limited
to rare patients with poor echocardiographic windows. All
patients with unstable hemodynamics were stabilized with
balloon aortic valvuloplasty (BAV) before TAVR.
An annulus diameter of 18 to 21 mm was considered
appropriate for the 23-mm prosthesis and 21 to 24 mm
for the 26-mm prosthesis. In cases of borderline sizes (20.5
to 21.5 mm), aortography was performed during balloon
pre-dilation with a 23-mm balloon, and the optimal valve
size was selected based on the presence or absence of aortic
regurgitation at full balloon inflation.
Computed tomographic (CT) was also systematically per-
formed to assess the feasibility of the transfemoral approach. A
minimum diameter of 7 and 8 mm was required for the 23-
and 26-mm SAPIEN valves, respectively, and 6 and 6.5 mm
for the SAPIEN XT valves, respectively. Before percutaneous
implantation, we also confirmed the absence of calcified plaque
at the area of the femoral puncture site.
Patient preparation and procedure. The procedures were
performed using the SAPIEN valve up to October 2009,
and the SAPIEN XT valve thereafter. Both of these valves
have been described elsewhere (3–6,9–11). Briefly, the
SAPIEN valve is made of 3 bovine pericardial leaflets
matched for elasticity and thickness, sewn onto a stainless
steel stent frame partially covered with a synthetic polyeth-
ylene terephthalate fabric sealing cuff. The prosthesis is
crimped over the balloon of the RetroFlex delivery system.
The SAPIEN XT valve uses a cobalt chromium frame with
thinner struts and a more open cell structure to allow tighter
crimping. The valve is crimped over the shaft of the
NovaFlex delivery system, and mounted on the balloon after
introduction into the abdominal aorta.
Cardiac catheterization and pre-medication. All procedures
were performed in a conventional cardiac catheterization lab-
oratory with sterile precautions. For the surgical arterial cut-
anuscript received September 11, 2011; revised manuscript received December 14,
011, accepted January 5, 2012.
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463down approach (SAPIEN valve), the team was composed of 2
interventional cardiologists, a cardiac surgeon, and 2 nurses.
The cardiac surgeon was not always present for the percuta-
neous approach (SAPIEN XT valve). All the equipment was
present and ready to be used in the catheterization laboratory,
and both the anesthesiologist and the echocardiographer were
immediately available in case of any complications.
Patients were preloaded with aspirin (160 mg) and clopi-
dogrel (300 mg) and continued to take clopidogrel (75 mg) for
1 month and aspirin (75 to 160 mg) indefinitely. Heparin
(5,000 IU) was administered immediately after surgical cut-
down or placement of the vascular closure device.
Local anesthesia and sedation. Lidocaine 2% (20 to 30 ml)
was used for local anesthesia; it was injected into the skin,
into the subcutis, and around the femoral artery for percu-
taneous and surgical approaches. Additional doses of lido-
caine could be administered at any time during the proce-
dure at the discretion of the operator. Conscious sedation
consisted of intravenous administration of midazolam (1
mg) and nalbuphine (5 mg) at the start of the procedure.
Additional half or full doses of each could be administered
at the discretion of the operator.
Procedure. The techniques of SAPIEN and SAPIEN XT
alve implantation have been described in detail elsewhere
9–11). Briefly, in our center, supravalvular aortography was
erformed to select the optimal view aligning all cusps in a
ingle plane. The selected femoral artery was cut down or
pre-closed” with a 10-Fr ProStar XL (Abbott, Chicago,
llinois). After crossing the aortic valve, a 260-cm-long 0.035-
nch Amplatz Extra-Stiff J-tip guidewire (COOK, Bjaevers-
ov, Denmark) was placed in the left ventricle. BAV was
erformed with rapid ventricular pacing (RVP, 180 to 220
eats/min) using a 20- or 23-mm balloon in accordance with
he valve size. Valve positioning was based on fluoroscopy
sing annular calcification as a landmark, and serial (5 to 10
l) supra-annular aortography to validate the position of the
alve during RVP. The prosthesis was delivered also using
VP. Removal of the sheath was cautiously achieved with
erial contralateral angiograms to detect iliofemoral complica-
ions. The femoral arteriotomy was then closed surgically or by
sing the ProStar device. In the absence of a new left bundle
ranch block or atrioventricular block; the pacing lead was
emoved at the end of the procedure. Patients were monitored
n intensive care unit for 24 h after valve implantation.
Data collection. Clinical and TTE parameters were obtained
t baseline, discharge, and 1 month, and the data were entered
nto our institutional database. For the patients from remote
nstitutions (16%), outcomes at 30 days were obtained by
elephonic interview of the referring physician and exchange of
TE reports. No patient was lost for follow-up.
Endpoint deﬁnitions. The primary safety endpoint was a
ombination of all-cause mortality, major stroke, life-
hreatening bleeding, stage 3 acute kidney injury (AKI),
eriprocedural myocardial infarction (MI), major vascular complication, and repeat procedure for valve-related dys-
unction at 30 days. All complications were reported accord-
ng to the Valve Academic Research Consortium (VARC)
lassification (12).
Secondary endpoints included: conversion to general anes-
hesia and need for vasopressors during the procedure, device
uccess according to the VARC definition (defined as success-
ul vascular access, delivery, and deployment of the device,
uccessful retrieval of the delivery system with correct position
f the device, post-TAVR aortic valve area 1.2 cm2, and
mean aortic valve gradient 20 mm Hg or peak velocity 3
/s without moderate or severe prosthetic valve regurgitation),
ew York Heart Association (NYHA) heart failure functional
lass, transvalvular mean pressure gradient, effective aortic valve
rea, presence and severity of aortic valvular regurgitation,
nd/or mitral valve regurgitation on TTE.
Statistical analysis. Qualitative variables were expressed as
percentage, and quantitative variables as mean  SD or
median (25th to 75th interquartile range). Comparison of
numerical variables was performed with the Student t test or
Wilcoxon rank sum test, depending on variable distribution.
The chi-square test or Fischer exact test was used to
compare qualitative variables. All statistical tests were
2-sided. Differences were considered statistically significant
at p values 0.05. All data were analyzed using SPSS
software (version 17.0, IBM, Armonk, New York).
Results
The results are presented for the whole population and
stratified by valve type (SAPIEN: n  78, SAPIEN XT:
n  73).
Baseline characteristics. Baseline clinical characteristics are
hown in Table 1. All patients were severely symptomatic. The
ean logistic EuroSCORE was 22.8%, and significantly lower
n the SAPIEN XT group (17.4% vs. 27.8%, p  0.0001).
istory of MI, coronary artery bypass graft, BAV, and chest
rradiation were less frequent in the SAPIEN XT group. All
ther variables were comparable in the 2 groups.
Baseline TTE data (Table 2) confirmed the severity of
ortic stenosis, similar in the 2 groups. Left ventricular
jection fraction was moderately, but significantly, lower in
he SAPIEN group due to selection of more severely ill
atients per protocol.
Procedural outcomes. The results are shown in Table 3.
ransarterial access was well tolerated in all cases and consisted
f surgical cutdown in all SAPIEN cases and percutaneous
pproach in all but 2 patients in the SAPIEN XT group.
The prosthesis was placed in the appropriate position in
ll cases. A single valve was implanted in all cases, and there
as no valve embolization. Procedural device success rate
as 95.4% in the overall population. Balloon post-dilation
as used to expand the valve and to minimize the leak inase of severe aortic regurgitation (grade 3) immediately
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 4 6 1 – 7
Durand et al.
TAVR Using Local Anesthesia
464after TAVR. This strategy was adopted in 12 (7.9%)
patients (7 [9.0%] in the SAPIEN group vs. 5 [6.8%] in the
SAPIEN XT group, p  0.629). Procedural failure was
related to unsuccessful vascular access in 2% or severe aortic
regurgitation (grade 3) in 2.6%.
Conversion to emergent cardiovascular surgery was re-
quired in only 5 SAPIEN cases (3.3%) (1 aortic dissection,
1 aortic annulus rupture with tamponade, 2 vascular rup-
tures, and 1 major aortic regurgitation). Conversion to
general anesthesia in the cardiac catheterization laboratory
before transfer to the operating room occurred in only 1
patient (annulus rupture). Two patients (aortic dissection and
annulus rupture) did not survive surgery, whereas the other 3
patients had uneventful outcomes. There was no conversion to
Table 1. Baseline Characteristics
Overall Population
(N  151)
SAPIEN
(n  78)
SAPIEN XT
(n  73) p Value
Age, yrs 83.3 6.4 83.9 5.8 82.7 6.9 0.19
Female 89 (58.9) 43 (55.1) 46 (63.0) 0.32
Hypertension 105 (69.5) 52 (66.7) 53 (72.6) 0.43
Diabetes 41 (27.2) 18 (23.1) 23 (31.5) 0.24
Previous MI 37 (24.5) 29 (37.2) 8 (11.0) 0.0001
Previous PCI 39 (25.8) 22 (28.2) 17 (23.3) 0.49
Previous CABG 26 (17.2) 18 (23.1) 8 (11.0) 0.049
Atrial ﬁbrillation 61 (40.4) 29 (37.2) 32 (43.8) 0.41
Pacemaker 15 (9.9) 10 (12.8) 5 (6.8) 0.22
Previous BAV 72 (47.7) 49 (62.8) 23 (31.5) 0.0001
PAD 20 (13.2) 8 (10.3) 12 (16.4) 0.26
Porcelain aorta 8 (5.3) 3 (3.8) 5 (6.8) 0.48
Previous stroke 8 (5.3) 4 (5.1) 4 (5.5) 1.00
Creatinine, mol/l 113 52 118 43 109 60 0.30
COPD 51 (33.8) 29 (37.2) 22 (30.1) 0.36
Chest irradiation 16 (10.6) 12 (15.4) 4 (4.5) 0.048
Neoplasia 34 (22.5) 22 (28.2) 12 (16.4) 0.08
NYHA functional class
III or more
115 (76.1) 63 (80.8) 52 (71.2) 0.10
Logistic EuroSCORE, % 22.8 11.8 27.8 11.1 17.4 10.0 0.0001
Values are mean SD or n (%).
BAV  balloon aortic valvuloplasty; CABG  coronary artery bypass graft; COPD  chronic
obstructive pulmonary disease; LVEF left ventricular ejection fraction; MImyocardial infarc-
tion; PAD peripheral artery disease; PASP pulmonary artery systolic pressure; PCI percuta-
neous coronary intervention.
Table 2. Baseline Echocardiographic Characteristics
Overall Population
(N  151)
Aortic annulus diameter, mm 21.2 1.5
Mean aortic gradient, mm Hg 44.6 17.1
Aortic valve area, cm2 0.67 0.15
PASP, mm Hg 42.7 13.2
LVEF, % 55.9 15.7
Values are mean SD.Abbreviations as in Table 1.general anesthesia or surgery in the SAPIEN XT group.
Hemodynamics remained remarkably stable at each step of the
procedures. Vasopressors were required in only 7 patients
(5.5%), including those just described above and 2 patients who
had prolonged hypotension after valve delivery.
Procedural duration was markedly shorter in the
SAPIEN XT group, whereas contrast volume was greater in
this group, due to additional use of contrast associated with
the “pre-close” technique.
30-day safety endpoint. The results are shown in Table 4.
In the overall population, the combined 30-day safety
endpoint was reached in 15.9% (17.9% vs. 13.7% with
SAPIEN and SAPIEN XT, respectively, p 0.47), includ-
ing death (6.6%, 60% of cardiovascular origin), major stroke
(2.0%), life-threatening bleeding (7.9%), stage 3 AKI
(0.7%), periprocedural MI (2.0%), major vascular compli-
cation (7.9%), and repeat procedure for valve-related dys-
function (2.0%). According to the VARC definition, bleed-
ing was life threatening in 7.9%, major in 11.3%, and minor
in 3.3%. These safety endpoints were similar with the 2
models of valves. Failure of vascular closure devices occurred
in 7 patients (9.6%) in the SAPIEN XT group, requiring
endovascular stent graft in 4 patients and vascular surgery in
3 patients. Finally, a permanent pacemaker was required in
5.3% of the overall population.
Secondary endpoints. Secondary endpoints are shown in
Table 5. NYHA heart failure functional class was dramat-
ically improved at 30 days. Hemodynamic parameters,
aortic valve area, and mean valvular gradient were also
markedly improved. Moderate-to-important aortic regurgi-
tation was infrequent (grade 3 in 2.6%). These results
were comparable in the SAPIEN and SAPIEN XT groups.
Discussion
Local anesthesia and conscious sedation have been our
choice since the first-in-man case in 2002. The trans-septal
antegrade approach used in compassionate cases via the
femoral vein in our earliest series did not require general
anesthesia (1,2). Several cases of percutaneous retrograde
approach were also performed at this early phase with the
same strategy. We thus became rapidly convinced of the
SAPIEN
(n  78)
SAPIEN XT
(n  73) p Value
21.1 1.5 21.3 1.5 0.06
41.4 15.1 48.1 18.5 0.03
0.67 0.16 0.66 0.15 0.81
43.8 12.4 41.7 13.9 0.26
52.7 17.1 59.3 13.3 0.02
rtic gra
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465feasibility, safety, and tolerance of this strategy. We have
continued to use this strategy for all cases of transfemoral
retrograde approach with or without surgical cutdown. To
Table 3. Procedural Outcomes
Overall Populati
(N  151)
Surgical cutdown 80 (53.0)
Conversion to general anesthesia 5 (3.3)
Vasopressors 7 (5.5)
Device success 144 (95.4)
Successful vascular access 148 (98.0)
Successful implantation 148 (100)*
Correct position 148 (100)*
AVA 1.2 cm2 148 (100)*
MAG 20 mm Hg 148 (100)*
AR grade 3 4 (2.6)
Only 1 valve implanted 148 (100)*
Procedural duration, min 136.6 47.0
X-ray time, min 24.4 18.3
Contrast volume, ml 185.2 96.4
Values are n (%) or mean SD. *Events were only evaluated in patien
AR aortic regurgitation; AVA aortic valve area; MAGmean ao
Table 4. 30-Day Safety Analysis
Overa
(
Combined-safety endpoint 2
30-day death
All cause 1
Cardiovascular cause
Stroke
Major stroke
Minor stroke
Transient ischemic attack
Bleeding
Life-threatening bleeding 1
Major bleeding 1
Minor bleeding
Transfusions 4
AKI
Stage 3 AKI
Stage 2 AKI
Stage 1 AKI 3
Vascular complications
Major vascular complication 1
Minor vascular complication 2
Periprocedural MI
Repeat procedure for valve-related dysfunction
Pacemaker
Days from procedure to CCU discharge 2.
Days from procedure to discharge 7.
Values are n (%) or median (25th–75th interquartile range).AKI acute kidney injury; CCU coronary care unit; MImyocardial infarour knowledge, the feasibility and safety of TAVR using
local anesthesia has never been previously prospectively
reported in a large series of consecutive patients. The main
SAPIEN
(n  78)
SAPIEN XT
(n  73) p Value
78 (100) 2 (2.7) 0.0001
5 (6.5) 0 (0) 0.06
6 (7.8) 1 (1.4) 0.12
73 (93.6) 71 (97.3) 0.28
76 (97.4) 72 (98.6) 0.32
76 (100)* 72 (100)* 1.0
76 (100)* 72 (100)* 1.0
76 (100)* 72 (100)* 1.0
76 (100)* 72 (100)* 1.0
3 (3.8) 1 (1.4) 0.31
76 (100)* 72 (100)* 1.0
151.7 2.7 105.9 40.3 0.0001
25.9 23.1 22.5 9.0 0.18
139.4 53.7 243.5 107.1 0.001
successful vascular access.
dient.
ulation
1)
SAPIEN
(n  78)
SAPIEN XT
(n  73) p Value
) 14 (17.9) 10 (13.7) 0.47
6 (7.7) 4 (5.5) 0.74
4 (5.1) 2 (2.7) 0.45
1 (1.3) 2 (2.7) 0.61
1 (1.3) 1 (1.4) 1.0
0 (0) 1 (1.4) 0.48
6 (7.7) 6 (8.2) 0.90
) 9 (11.5) 9 (12.3) 0.88
1 (1.3) 4 (5.5) 0.19
) 26 (33.3) 16 (21.9) 0.12
1 (1.3) 0 (0) 1.0
1 (1.3) 0 (0) 1.0
) 23 (29.5) 16 (21.9) 0.29
6 (7.7) 6 (8.2) 0.90
) 7 (9.0) 13 (17.8) 0.11
2 (2.6) 1 (1.4) 1.0
3 (3.8) 0 (0) 0.25
5 (6.4) 3 (4.1) 0.72
3.0) 1.5 (1.0–2.0) 2.0 (1.0–3.0) 0.66
9.0) 8.0 (7.0–9.0) 6.0 (5.0–9.0) 0.003on
ts withll Pop
N  15
4 (15.9
0 (6.6)
6 (4.0)
3 (2.0)
2 (1.3)
1 (0.7)
2 (7.9)
8 (11.9
5 (3.3)
2 (27.8
1 (0.7)
1 (0.7)
9 (25.8
2 (7.9)
0 (13.2
3 (2.0)
3 (2.0)
8 (5.3)
0 (1.0–
0 (5.0–ction.
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466goal of the present study was to report the results obtained
in our institution with the exclusive use of this simplified
strategy. We further sought to compare the results obtained
with the SAPIEN and the SAPIEN XT valves.
General versus local anesthesia. Transfemoral TAVR is
generally performed with general anesthesia as shown in the
FRANCE (FRench Aortic National CoreValve and Ed-
wards) registry reporting 73.7% and 82% rates of general
anesthesia with the SAPIEN and CoreValve devices, respec-
tively (6). Other series are reporting exclusive use of general
anesthesia for SAPIEN valve implantation (4,9–11,13).
Among the arguments favoring general anesthesia are greater
patient compliance, complete airway control, better procedural
tolerance, and the capability to rapidly initiate cardiac support.
However, with the introduction of smaller sheath sizes, local
anesthesia with conscious sedation is currently emerging as a
valuable alternative. In our experience, lack of pain, patient
tolerance of femoral access, and RVP were consistently ob-
served. Endotracheal intubation was not required to improve
the patient’s comfort and compliance.
Advantages to local anesthesia include more stable he-
modynamics, less need for inotropic and/or vasopressor
support (with the risk of subsequent vasoconstriction of the
arterial access), lack of endotracheal intubation/ventilation/
Table 6. Comparative Results With Randomized and Observational Studies
Variables
Rouen TF
(n  151)*
Partner-A
(n  244
30-day or in-hospital death 10 (6.6) 8 (3.3)
Major stroke 3 (2.0) 7 (2.9)
Signiﬁcant bleeding 12 (7.9) 23 (9.5)†
Transfusions 42 (27.8) NA
Stage 3 AKI and/or renal replacement therapy 1 (0.7) 6 (2.5)
Major vascular complications 12 (7.9) 34 (14.0
Periprocedural MI 2 (1.3) 0 (0)
Repeat procedure for valve-related dysfunction 3 (2.0) 3 (3.8)
30-day AR grade 3 4 (2.6) 38 (13.1
Pacemaker 8 (5.3) 5 (6.4)
Values are n (%). *Evaluated with Valve Academic Research Consortium definition. †Only available
Table 5. 30-Day Secondary Endpoints
Overall Populat
(N  151)
NYHA functional class III or more 8 (5.3)
Mean aortic gradient, mm Hg 9.5 2.9
Aortic valve area, cm2 1.82 0.24
LVEF, % 61.4 12.2
AR grade 3 4 (2.6)
MR grade 3 5 (3.3)
PASP, mm Hg 40.4 13.4
Values are n (%) or mean SD.
MRmitral regurgitation; NYHA New York Heart Association; otNA not available; TF transfemoral; other abbreviations as in Tables 3 and 4.extubation, fewer vascular access sites, and shorter procedural
duration and hospital stay. In our series, conversion to general
anesthesia before transfer to surgery was required in a single
case for major aortic complication. Periprocedural cardiopul-
monary support was not required in our series. Conversion to
thoracic or vascular surgery was limited to 5 cases (3%).
TEE versus no TEE. General anesthesia is required for ad-
unct intraprocedural TEE. In the FRANCE registry (6),
6.3% of the transfemoral procedures were performed with
ntraprocedural TEE up to 100% in other registries as well
s in the pivotal PARTNER-US trial (4,9–11,13). Using
nly fluoroscopic guidance without intraprocedural TEE
acilitated the use of conscious sedation in lieu of general
nesthesia. With our strategy, procedural success remained
ery high (95.4%) and comparable to other series. Appropriate
alve positioning by fluoroscopy and repeated aortography was
chieved without valve migration or malposition. Without
EE, immediate results and complications were adequately
ssessed using hemodynamics, angiography, and TTE.
Edwards SAPIEN versus SAPIEN XT valves. This is one of the
rst studies to compare the SAPIEN with the SAPIEN XT
alve: The comparison of outcomes with the 2 models of
dwards valves showed no difference in stroke, AKI,
eriprocedural MI, and vascular complications. Although
the Edwards Prosthesis
Partner-B
(n  179)
SOURCE TF
(n  463)
FRANCE TF-Edwards
(n  95)
Vancouver TF
(n  205)*
9 (5.0) 29 (6.3) 8 (8.4) 14 (6.8)
9 (5.0) 11 (2.4) 4 (4.2) 5 (2.4)
30 (16.8)† NA NA 29 (14.1)
NA 46 (9.9) 8 (8.4) NA
2 (1.1) 6 (1.3) 1 (1.0) 1 (0.5)
29 (16.2) 49 (10.6) 6 (6.3) 24 (11.7)
0 (0) 3 (0.7) 2 (2.0) NA
3 (1.7)* NA NA 0 (0)
23 (15.0) 7 (1.5) NA† NA†
6 (3.4) 31 (6.7) 5 (5.3) 11 (5.4)
lobal cohort, including CoreValve or transapical approach.
SAPIEN
(n  78)
SAPIEN XT
(n  73) p Value
5 (6.4) 3 (4.1) 0.72
9.6 2.6 9.5 3.3 0.94
1.80 0.21 1.84 0.27 0.51
58.4 11.8 65.0 11.8 0.33
3 (3.8) 1 (1.4) 0.31
3 (3.8) 2 (2.7) 1.0
40.7 11.7 40.0 15.2 0.76
reviations as in Tables 1 and 3.Using
TF
)
)
)
in the gion
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467the 30-day mortality was lower in the SAPIEN XT group
(5.5% vs. 7.7%), it was not statistically significant. As
expected, the percutaneous approach used in this group was
associated with significantly shorter procedural duration and
hospital stay. As observed in other European series, patients
receiving SAPIEN XT valves were less sick, as shown by the
lower logistic EuroSCORE in our SAPIEN XT group.
Even if indications of TAVR have been restricted to
inoperable and high surgical risk patients (logistic Euro-
SCORE 20% and/or Society of Thoracic Surgeons (STS)
score 10%) in our institution, there is a trend for consid-
ering TAVR in lower-risk patients, in particular 85-year-
old patients when the transfemoral approach is feasible. An
extension of indications to lower risk patients should be
evaluated through randomized studies and/or well con-
trolled prospective registries.
Comparison of our results to other reports. Our population
was comparable to that of many other series (Table 6). In
our overall population, the combined safety endpoint at 30
days was reached in 15.9%. The use of the recent VARC
definition for assessing safety at 30 days does not allow for
the comparison to previous reports, which did not use
standardized definitions (12). To our knowledge, only 1
study reported the results of the Edwards prosthesis using
the VARC definitions (13). In this study, in which general
anesthesia was used, the combined safety endpoint at 30
days was comparable to ours (18.4%) as well as other
individual endpoints (13). Even when compared with stud-
ies using non-VARC endpoints, our overall results look
similar (Table 6). Thirty-day mortality, incidence of stroke,
periprocedural MI, major vascular complications, and
bleeding complications were comparable to other series in
which most procedures were performed with general anes-
thesia and adjunct TEE.
Study limitations. This prospective study reflects a single-
center experience on a relatively limited number of patients.
We excluded our TAVR patients treated before May 2006
with another approach (compassionate procedures; ante-
grade cases), other delivery systems (RetroFlex 1 and 2), and
different screening process (no CT angiography). However,
the results are those of an experienced team, with a
consistent strategy for patient selection and procedural
management. Thus, they may not be reproducible by less
experienced teams. Finally, the study was underpowered for
a definitive comparison of the SAPIEN versus the SAPIEN
XT prosthesis.
Conclusions
The results of this single-center, prospective registry dem-
onstrated the feasibility and safety of transfemoral TAVR
performed using exclusively local anesthesia and fluoro-scopic guidance. The benefit of this simplified strategy
deserves further study in a larger series of patients receiving
the SAPIEN XT valve. Such a strategy might facilitate
expanded use of TAVR in the future.
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